Clinical Trials Logo

Clinical Trial Summary

Implementation of an evidence-based and best practices acute RRT pathway aiming to decrease acute RRT program and healthcare systems costs while improving important patient-reported outcomes.


Clinical Trial Description

Providing acute dialysis to critically ill patients in ICU settings is resource and cost intensive. The daily costs of acute dialysis can range from $528/day for intermittent hemodialysis to $865/day for continuous renal replacement therapy. Providing acute dialysis in ICU settings requires a specialized team of nurses, educators, physicians and stakeholders to ensure its safe and effective prescription and delivery. Acute dialysis is typically delivered to some of the most acutely ill patients admitted to the ICU to support organ function and sustain life. At present, there is not a standardized approach to the prescription and delivery of acute dialysis therapy in ICUs across Alberta. The DIALYZING WISELY program will implement a standardized approach to the delivery of best practices for acute dialysis therapy to all patients who receive treatment across ICUs in Alberta. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05186636
Study type Observational
Source University of Alberta
Contact Dawn Opgenorth, RN
Phone 780 492-4698
Email [email protected]
Status Not yet recruiting
Phase
Start date July 1, 2022
Completion date June 30, 2025

See also
  Status Clinical Trial Phase
Completed NCT01920542 - Dexmedetomidine on Pediatric Heart Operation N/A
Recruiting NCT04334707 - Kidney Precision Medicine Project
Completed NCT02765464 - Acute Kidney Injury in Critically Ill Patients
Completed NCT04600271 - Acute Renal Injury After Major Elective Non-Cardiac Surgery
Completed NCT02838667 - Prevention and Early Detection and Intervention of Post-Coronary Artery Bypass Grafting Surgery (CABG) Acute Kidney Injury (AKI) N/A
Completed NCT02974946 - Kidney Protection Using the RenalGuard® System in Cardiac Surgery N/A
Not yet recruiting NCT05145283 - Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation Phase 2
Completed NCT01807195 - Acute Renal Injury Associated Contrast in Intensive Care Unit Patients N/A
Recruiting NCT02743156 - Minimizing Contrast Utilization With IVUS Guidance in Coronary Angioplasty to Avoid Acute Nephropathy Phase 4
Recruiting NCT02417896 - Short Term Spironolactone for Prevention of Acute Kidney Injury After Cardiac Surgery N/A